Those findings, supported by biological evidence from genetically engineered mouse models, suggest KRAS alterations drive PDAC initiation while subsequent mutations in CDKN2A and other tumor suppressors are rate-limiting for tumor progression [181]. This evidence concerns the gene KRAS and neoplasm.